KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Change in Accured Expenses: 2017-2025

Historic Change in Accured Expenses for Twist Bioscience (TWST) over the last 8 years, with Sep 2025 value amounting to $1.1 million.

  • Twist Bioscience's Change in Accured Expenses fell 41.59% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.6 million, marking a year-over-year decrease of 16.04%. This contributed to the annual value of $6.6 million for FY2025, which is 16.04% down from last year.
  • As of Q3 2025, Twist Bioscience's Change in Accured Expenses stood at $1.1 million, which was down 91.97% from $14.1 million recorded in Q2 2025.
  • In the past 5 years, Twist Bioscience's Change in Accured Expenses registered a high of $14.1 million during Q2 2025, and its lowest value of -$12.9 million during Q3 2022.
  • Moreover, its 3-year median value for Change in Accured Expenses was $1.9 million (2024), whereas its average is $1.9 million.
  • As far as peak fluctuations go, Twist Bioscience's Change in Accured Expenses soared by 1,165.23% in 2021, and later slumped by 561.59% in 2022.
  • Quarterly analysis of 5 years shows Twist Bioscience's Change in Accured Expenses stood at -$3.6 million in 2021, then fell by 2.54% to -$3.7 million in 2022, then plummeted by 36.65% to -$5.1 million in 2023, then plummeted by 133.36% to -$11.8 million in 2024, then tumbled by 41.59% to $1.1 million in 2025.
  • Its Change in Accured Expenses was $1.1 million in Q3 2025, compared to $14.1 million in Q2 2025 and $3.2 million in Q1 2025.